Edwards Lifesciences (NYSE: EW) today announced new data demonstrating long-term benefits with its Sapien heart valve system.

Five-year data from the PARTNER 3 trial showed that among low-risk patients with severe, symptomatic aortic stenosis, ...

Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data, which showed superior clinical ...

Investing.com -- Edwards Lifesciences (NYSE:EW) stock rose 4.5% following the presentation of new data showing long-term benefits and valve performance of its SAPIEN 3 TAVR.

Medtronic (NYSE: MDT) today announced the launch of its Stedi extra support guidewire for use with its Evolut TAVR platform.

The companies have teamed to develop an alternative to TAVR that combines the benefits of a less-invasive procedure with the ...

Using a catheter to repair or replace a valve is a fairly recent breakthrough in the world of interventional cardiology. Early on, it was a procedure reserved largely for patients with a faulty aortic ...

Facing an upcoming surgical procedure often brings stress and anxiety, but not for Della de Corse. When she learned she would ...

Researchers support limiting these surgeries to centers that do the most cases, though true high-volume hospitals remain rare ...